Feed aggregator

Cancer cells killed with their own carbon monoxide

World Pharma News - Fri, 11/06/2026 - 11:00
What if we could use a cancer’s own byproduct to make drugs that destroy tumor cells from the inside? That is exactly what Katsunori Tanaka and his team have done at the RIKEN Pioneering Research Institute (PRI) in Japan. Published in Nature Communications, the proof-of-concept study describes how a synthetically designed compound uses the excess carbon monoxide produced in tumor cells to trigger the production of anti-cancer drugs within the cells themselves.

AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes

World Pharma News - Thu, 11/05/2026 - 11:00
AstraZeneca and Oracle Health and Life Sciences announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner.

Can we stop antibiotic resistance in ruining promising drugs before they reach patients?

World Pharma News - Wed, 11/04/2026 - 11:00
What if we could predict in early development, which antibiotics bacteria are most likely to become resistant to? In a review published in Nature Reviews Microbiology, researchers from the HUN-REN Biological Research Centre, Szeged (HUN-REN BRC Szeged) and the Hungarian Centre of Excellence for Molecular Medicine (HCEMM) in Szeged propose a five-step decision-making framework that could help identify resistance risks early, refine promising drug candidates and prevent costly failures.

New therapeutic approach for the brain disorder SCA3

World Pharma News - Tue, 11/03/2026 - 11:00
Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London, and Portugal, have developed and successfully tested in human neurons cultured in the lab a new approach for treating the rare neurodegenerative disease Spinocerebellar Ataxia Type 3 (SCA3).

FDA launches new program to advance neuroscience medical product development

World Pharma News - Mon, 11/02/2026 - 11:00
The U.S. Food and Drug Administration announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments. NAIN is designed to advance the science, tools, and regulatory approaches needed to support the development of medical products for conditions affecting the brain and nervous system.

Drug substance reduces blood vessel malformations in the brain

World Pharma News - Fri, 10/30/2026 - 11:00
Researchers have identified a substance that reduces blood vessel lesions in the brain in the disease Cerebral Cavernous Malformation (CCM). The substance is already used to treat brain tumours in children and could therefore relatively rapidly be repurposed to treat CCM, hopefully replacing surgery as the currently only treatment option.

Creating 'satellite maps' of proteins could transform drug therapies

World Pharma News - Thu, 10/29/2026 - 09:39
Much like a satellite provides a full picture of Earth, a ground-breaking new technology can generate thousands of detailed “satellite maps” showing where individual proteins are located and distributed across an entire tissue in the body or brain.

A University at Buffalo researcher has developed this novel technology, called hexagonal micro-scaffold assisted spatial proteomics (hex-MASP), which has the potential to transform how researchers study and create new drugs.

New AI platform helps uncover promising cancer drug combinations

World Pharma News - Wed, 10/28/2026 - 11:00
UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.

The platform, called MAESTRO and described in Advanced Science, uses large language models, or LLMs, to analyze scientific knowledge about how drugs work and the biological pathways cancer cells use to survive treatment.

AI aids in the development of new active ingredients

World Pharma News - Tue, 10/27/2026 - 11:00
Nature offers a virtually limitless variety of chemical substances. Although these have been optimized over millions of years of evolution for their respective purposes, they have not been optimized for use as active ingredients in humans. For decades, researchers have therefore been attempting to genetically reprogram microbial producers of active ingredients so that they produce variants of their natural compounds with improved pharmaceutical properties.

Transparent minispheres reveal that some look-alike cancer drugs part ways in 3D

World Pharma News - Mon, 10/26/2026 - 11:00
Researchers at Uppsala University have adapted Cell Painting, a widely used imaging method in drug discovery, to look at individual cells inside small 3D clusters of cancer cells. Two drugs that looked almost identical in ordinary flat cell cultures behaved differently in 3D, and the team linked the difference to how each drug switches on the cell’s p53 stress response.

Researchers discover Achilles' heel of antibiotic-resistant bacteria

World Pharma News - Fri, 10/23/2026 - 10:00
Even highly antibiotic-resistant bacteria become more vulnerable when their cell wall transport system is disrupted, according to a new study from Umeå University in Sweden. The discovery reveals a previously overlooked weakness that could help researchers develop new strategies to combat antibiotic resistance.

“The search for new antibiotics remains crucial, but we also need smarter ways to extend the lifespan of the antibiotics we already have.

Lactation drug could reduce breast cancer risk after childbirth

World Pharma News - Thu, 10/22/2026 - 10:00
An international team of scientists has found that a lactation drug could reduce the risk of breast cancer in mothers after childbirth.

Cabergoline, a medication used to stop milk production after pregnancy loss or when breastfeeding is not possible, is generally well tolerated by patients with few side effects. But it may also offer unexpected benefits.

Google.org awards $2.3 million USD to University of Toronto researchers to advance AI-powered peptide drug discovery

World Pharma News - Wed, 10/21/2026 - 10:00
A group of scientists led by Joseph Brown, assistant professor at the Leslie Dan Faculty of Pharmacy, has received $2.3 million USD in funding to develop a database and AI training model to identify peptides with therapeutic potential. The project is funded through the Google.org Impact Challenge: AI for Science initiative.

The newly funded initiative, OpenPep, will lead to an open access database that will allow researchers to use artificial intelligence (AI) to predict which peptides will bind to target proteins.

FDA issues final guidance on Prescription drug apps and software

World Pharma News - Tue, 10/20/2026 - 10:00
The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines. The guidance ends longstanding uncertainty by providing recommendations about when app content is subject to FDA submission requirements, when an app should be mentioned on a drug’s official label, and what companies should submit to the agency.

Unsuspected discovery of abnormal antibodies could explain pediatric cancer

World Pharma News - Mon, 10/19/2026 - 10:00
A team of scientists in Norway has found evidence for a new, previously unknown mechanism for the development of cancer in children: they seem to produce an unusual amount of aberrant antibodies against the building blocks that make up the DNA repair machinery, a diverse set of hundreds of proteins which identify and correct damage or errors in the genome. This important discovery could open the door to the early screening of small children, in the hope of ultimately preventing them from developing such pediatric cancers years in their teenage years.

How cancer cells lose dangerous DNA

World Pharma News - Fri, 10/16/2026 - 10:00
Aggressive tumors often contain large amounts of exchromosomal DNA. Removing this DNA from the nuclei of cancer cells could improve patient outcomes, an international team led by Anton Henssen of the Experimental and Clinical Research Center reports in Nature Genetics.

Cells from rapidly growing, highly metastatic tumors often contain numerous rings of extrachromosomal DNA (ecDNA).

Abbott launches 'Mind Your Behind' campaign to encourage Americans 45+ to screen for colorectal cancer

World Pharma News - Thu, 10/15/2026 - 10:00
Abbott, the global healthcare leader, launched “Mind Your Behind,” a new Cologuard Plus® awareness campaign featuring baseball legend and three-time MVP Albert “The Machine” Pujols and catcher for the Seattle Mariners Cal “The Big Dumper” Raleigh to encourage adults to prioritize colorectal cancer screening.

Nearly one billion people could live with osteoarthritis by 2050

World Pharma News - Wed, 10/14/2026 - 10:00
Almost one billion people are projected to be living with osteoarthritis by 2050, up from about 600 million in 2023, and there remains no cure and no drug that can stop or slow the disease, according to a new roadmap published in The Lancet.

A Curtin University-led group of international researchers is calling for stronger health policy action to arrest the growing global disability burden.

Pharmaceutical company marketing negatively influences prescribing

World Pharma News - Tue, 10/13/2026 - 10:00
Doctors’ prescribing habits are heavily influenced by payments, gifts, and free meals from pharmaceutical companies, leading to more expensive, less appropriate and more drugs being prescribed, a new Cochrane review finds. This can seriously harm both individual patients and health systems.

Pharmaceutical companies use a variety of strategies to market and promote their drugs.

NIH grant awarded to treat breast cancer with bacteria

World Pharma News - Mon, 10/12/2026 - 10:00
A scientist at Weill Cornell Medicine is working with colleagues at the University of Massachusetts Amherst on new, complementary research efforts engineering therapeutic Salmonella to target critical gaps in treatment for drug-resistant triple-negative breast cancers. The team has received a five-year, $13.1 million grant, the first of its kind for bacteria cancer therapies awarded by the U.S. National Institutes of Health,